53882-12-5
53882-12-5 structure
- Name: Lodoxamide
- Chemical Name: 2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid
- CAS Number: 53882-12-5
- Molecular Formula: C11H6ClN3O6
- Molecular Weight: 311.63500
- Catalog: Signaling Pathways GPCR/G Protein Histamine Receptor
- Create Date: 2018-08-12 08:53:28
- Modify Date: 2024-01-05 10:35:12
-
Lodoxamide is an antiallergic compound acting as a mast-cell stabilizer for the treatment of asthma and allergic conjunctivitis.
| Name | 2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid |
|---|---|
| Synonyms |
UNII-SPU695OD73
Acetic acid,2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)bis(2-oxo Lodoxamidum [INN-Latin] N,N'-(2-Chlor-5-cyan-m-phenylen)-dioxamsaeure Alomide (TN) Lodoxamidum Lodoxamida [INN-Spanish] N,N'-(2-Chlor-5-cyan-3-phenylen)dioxamsaeure N-N'-(2-chloro-5-cyano-m-phenylene)dioxamic acid Lodoxamida diesters of N,N'-(2-chloro-5-cyano-m-phenylene)dioxamic acid Lodoxamide |
| Description | Lodoxamide is an antiallergic compound acting as a mast-cell stabilizer for the treatment of asthma and allergic conjunctivitis. |
|---|---|
| Related Catalog | |
| In Vitro | Lodoxamide inhibits compound 48/80-induced histamine release and ionophore-induced 45Ca influx with associated histamine release in purified rat peritoneal mast cells[1]. The chemotactic response of eosinophils to fMLP as well as to IL-5 is significant and dose-dependent inhibited by Lodoxamide. Lodoxamide is also able to strongly inhibit the release of eosinophil peroxidase after IgA-dependent activation and, to a lesser extent, the release of eosinophil cationic protein and eosinophil-derived neurotoxin[2]. |
| In Vivo | Lodoxamide has been demonstrated to have cromolyn-like activity when studied in the rat peritoneal mast cell assay (PCA) model3 and in Ascaris antigen-sensitized rhesus monkeys. When given intravenously, orally, or intrabronchially by aerosol, lodoxamide significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge in Ascaris-sensitized. anesthetized rhesus monkeys[1]. Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation, decreased microvascular permeability, and increased compliance[3]. Patients treated with lodoxamide tromethamine demonstrate an improvement in daytime breathing difficulty, cough, sputum production, and sleep[4]. |
| References |
| Density | 1.78g/cm3 |
|---|---|
| Molecular Formula | C11H6ClN3O6 |
| Molecular Weight | 311.63500 |
| Exact Mass | 310.99500 |
| PSA | 156.59000 |
| LogP | 0.40388 |
| Index of Refraction | 1.673 |
| Storage condition | 2-8℃ |
| HS Code | 2926909090 |
|---|
|
~%
53882-12-5 |
| Literature: Journal of Medicinal Chemistry, , vol. 21, p. 930 - 935 |
|
~%
53882-12-5 |
| Literature: Journal of Medicinal Chemistry, , vol. 21, p. 930 - 935 |
|
~%
53882-12-5 |
| Literature: Journal of Medicinal Chemistry, , vol. 21, p. 930 - 935 |
| Precursor 3 | |
|---|---|
| DownStream 0 | |
| HS Code | 2926909090 |
|---|---|
| Summary | HS:2926909090 other nitrile-function compounds VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |